5 results
Protein-c-reactive as a marker of inflammation and cardiovascular disease in patients with schizophrenia: a cross-sectional analysis of a healthcare provider administrative claim database
-
- Journal:
- European Psychiatry / Volume 26 / Issue S2 / March 2011
- Published online by Cambridge University Press:
- 16 April 2020, p. 1488
-
- Article
-
- You have access
- Export citation
Cost-consequences Analysis of Desvenlafaxine Versus Usual Care in the Treatment of Major Depressive Disorder After Failure of First-line Treatment with a Selective-serotonin-reuptake-inhibitor (SSRI) in Spain
-
- Journal:
- European Psychiatry / Volume 30 / Issue S1 / March 2015
- Published online by Cambridge University Press:
- 15 April 2020, p. 1
-
- Article
-
- You have access
- Export citation
Modelling the Economic Impact of Desvenlafaxine Versus Venlafaxine as a Second Line Therapy of Major Depressive Disorder Patients in Spain
-
- Journal:
- European Psychiatry / Volume 30 / Issue S1 / March 2015
- Published online by Cambridge University Press:
- 15 April 2020, p. 1
-
- Article
-
- You have access
- Export citation
Influence of combinations of drugs that act on the CYP2D6 metabolic pathway in the treatment of major depressive disorder: A population-based study
-
- Journal:
- European Psychiatry / Volume 29 / Issue 6 / August 2014
- Published online by Cambridge University Press:
- 15 April 2020, pp. 331-337
-
- Article
- Export citation
C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice
-
- Journal:
- European Psychiatry / Volume 28 / Issue 3 / March 2013
- Published online by Cambridge University Press:
- 02 October 2011, pp. 161-167
-
- Article
- Export citation